Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.34 |
| ▸ | DRD2 | P14416 | 5/20 | 0.34 |
| ▸ | DRD1 | P21728 | 5/20 | 0.34 |
| ▸ | HRH1 | P35367 | 5/20 | 0.34 |
| ▸ | DRD3 | P35462 | 5/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | MLNR | O43193 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4037112 | 0.94 | HTR2A (0.38) | MAPK1ADRA2ADRD2DRD1HRH1 | |
| SCHEMBL4035884 | 0.90 | CACNA1H (0.36) | ADRA2ADRD1DRD3CHRM2HTR1A | |
| Hydrochloric Acid SCHEMBL4038349 | 0.89 | CACNA1H (0.35) | MAPK1ADRA2ADRD1DRD3CHRM2 | |
| SCHEMBL4043579 | 0.88 | HDAC3 (0.41) | HRH3MAOAACHEKDM4ECXCR1 | |
| SCHEMBL4046594 | 0.88 | CYP1A2 (0.35) | ADRA2ADRD2DRD1HRH1DRD3 | |
| Hydrochloric Acid SCHEMBL4039414 | 0.87 | CYP1A2 (0.34) | ADRA2ADRD2DRD1HRH1DRD3 | |
| SCHEMBL5425097 | 0.86 | CACNA1H (0.35) | MAPK1CYP1A2CYP2D6HRH3MAOA | |
| SCHEMBL6341181 | 0.86 | MAPK1 (0.36) | MAPK1ADRA2ADRD2DRD1HRH1 | |
| SCHEMBL6336542 | 0.85 | MAPK1 (0.36) | MAPK1ADRA2ADRD2DRD1HRH1 | |
| SCHEMBL4035177 | 0.84 | HRH3 (0.36) | HRH3MAOAACHEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284977-B1 | THIENODIBENZOAZULENE COMPOUNDS AS TUMOR NECROSIS FACTOR INHIBITORS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-06-24 | — | — | EP | claimed |
| US-20050171091-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA D.D. (HR) | 2005-08-04 | — | — | US | claimed |
| US-6897211-B2 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-05-24 | — | — | US | claimed |
| US-20030153750-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO | 2003-08-14 | — | — | US | claimed |
| EP-1284977-B1 | THIENODIBENZOAZULENE COMPOUNDS AS TUMOR NECROSIS FACTOR INHIBITORS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-06-24 | — | — | EP | disclosed |
| US-20050171091-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA D.D. (HR) | 2005-08-04 | — | — | US | disclosed |
| US-6897211-B2 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-05-24 | — | — | US | disclosed |
| US-20030153750-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153750-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | TNF, IL1B, IL1A | MAPK1 764/4885ADRA2A 948/4885DRD2 1902/4885 |
| US-20050171091-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | TNF, IL1B, IL1A | MAPK1 730/4885ADRA2A 971/4885DRD2 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.